FlandersBio on Twitter

Follow us on Twitter

Archive for May 2014 - News

Archive for May 2014 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO

30.05.2014

arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematological and solid tumors at the 50th annual meeting of the American Society of Clinical Oncology (ASCO; 30 May-3 June, 2014, Chicago, IL, USA). read more

arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates

28.05.2014

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X’s SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms. read more

ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE

28.05.2014

Ablynx [Euronext Brussels: ABLX] today announces it will present at the annual Jefferies 2014 Global Healthcare Conference at the Grand Hyatt in New York City on Monday, 2nd June 2014 at 11:30 a.m. EST (05:30 p.m. CET). read more

ThromboGenics Business Update

23.05.2014

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today issued a business update for the three month period ending 31 March 2014. read more

Cryo-Save Group N.V.: Convocation of extra-ordinary general meeting of shareholders to change name to Esperite N.V.

22.05.2014

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that, further to its 13 May 2014 announcement that it shall change its name to Esperite, it has convened an extra-ordinary general meeting of shareholders ('EGM') to be held on 2 July 2014, which is to implement this change and to resolve on the change of the Company's name to Esperite N.V. read more

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

21.05.2014

Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Biotech Value Fund Partners LP and Biotech Value Fund Inc. read more

CARDIO3 BIOSCIENCES ANNOUNCES Q1 2014 BUSINESS UPDATE AND CONFIRMS PREVIOUS OPERATIONAL AND FINANCIAL GUIDANCE

20.05.2014

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces its business update for the three-month period ending 31 March 2014. read more

MDxHealth Reports 10-Fold Reduction of Repeat Prostate Biopsies in ConfirmMDx Clinical Utility Study

20.05.2014

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the results of the ConfirmMDx® for Prostate Cancer clinical utility study will be published in the journal American Health and Drug Benefits (2014;7(3):129-134: www.AHDBonline.com). The study demonstrated a 10-fold reduction in the repeat biopsy rate in the ConfirmMDx-negative patient cohort as compared to the reported rate of repeat biopsy under the current standard of care. read more

Cardio3 BioSciences Signs First Sales Contract for C-Cathez(r)

20.05.2014

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, announces today that it has entered into a trade agreement with ViroMed Co., LTD for the use of Cardio3 BioSciences’ catheter C-Cathez® in the development of ViroMed’s VM202-CAD product in Korea. Financial terms were not disclosed. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print